STERIS plc’s (STE) growth in the fiscal second quarter of 2025 can be attributed to the robust performance of its Healthcare business. The company also benefits from the strong rebound prospects for its Applied Sterilization Technologies (“AST”) segment.Meanwhile, headwinds such as foreign currency risks and fierce competitive pressure are concerning.Year to date, shares of this Zacks Rank #3 (Hold) company have lost 2.1% against the industry’s 7.6% growth and the S&P 500’s 18.4% increase.The renowned provi ...